Product News

Share this article:

Johnson & Johnson subsidiary Centocor Ortho Biotech received FDA approval for Simponi, an injectable treatment for arthritis caused by immune-system disorders. According to an AP report, the drug is a potential blockbuster, and a follow-up to Remicade, a multibillion-dollar seller. Simponi will be marketing in the US by J&J, and in Europe by Schering-Plough.

 

FDA authorized a relaxed indication and distribution of Roche's and GlaxoSmithKline's antiviral drugs – Tamiflu and Relenza, respectively – in order to combat swine flu. Public health officials and volunteers will be allowed to distribute the meds, and both drugs will be available off-label, based on FDA's “Emergency Use Authorization” provision.

 

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.